346 related articles for article (PubMed ID: 1310577)
1. Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis.
Le Conte P; Joly V; Saint-Julien L; Gillardin JM; Carbon C; Yeni P
Am Rev Respir Dis; 1992 Feb; 145(2 Pt 1):424-9. PubMed ID: 1310577
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic activity of liposomal SJA-95: a new polyene macrolide antibiotic in experimental aspergillosis and cryptococcosis.
Desai SK; Naik SR
Biomed Pharmacother; 2009 May; 63(4):287-92. PubMed ID: 18848764
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
4. In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents.
Van Cutsem J
Chemotherapy; 1992; 38 Suppl 1():3-11. PubMed ID: 1319313
[TBL] [Abstract][Full Text] [Related]
5. R 51211 (itraconazole) therapy of murine cryptococcosis.
Graybill JR; Ahrens J
Sabouraudia; 1984; 22(6):445-53. PubMed ID: 6098031
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice.
Troke PF; Andrews RJ; Marriott MS; Richardson K
J Antimicrob Chemother; 1987 May; 19(5):663-70. PubMed ID: 3038824
[TBL] [Abstract][Full Text] [Related]
8. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
9. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
[TBL] [Abstract][Full Text] [Related]
10. Preparation, relative toxicity and therapeutic efficacy in mice and rats of liposomal HA-1-92, a new oxohexaene polyene macrolide antibiotic.
Harindran J; Chakraborty KK; Naik SR
J Pharm Pharmacol; 1999 Jul; 51(7):771-6. PubMed ID: 10467950
[TBL] [Abstract][Full Text] [Related]
11. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Prince RA; Chi J; Kontoyiannis DP
Antimicrob Agents Chemother; 2002 Oct; 46(10):3208-14. PubMed ID: 12234846
[TBL] [Abstract][Full Text] [Related]
12. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis.
Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y
J Antimicrob Chemother; 2006 Apr; 57(4):724-31. PubMed ID: 16446374
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of pulmonary mycoses].
Schaberg T; Lode H
Dtsch Med Wochenschr; 1992 Nov; 117(45):1725-9. PubMed ID: 1330477
[No Abstract] [Full Text] [Related]
14. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
Manavathu EK; Cutright JL; Chandrasekar PH
Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
[TBL] [Abstract][Full Text] [Related]
15. Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections.
Odds FC; Oris M; Van Dorsselaer P; Van Gerven F
Antimicrob Agents Chemother; 2000 Nov; 44(11):3180-3. PubMed ID: 11036047
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304.
Defaveri J; Salazar MH; Rinaldi MG; Graybill JR
Am Rev Respir Dis; 1990 Sep; 142(3):512-5. PubMed ID: 2202244
[TBL] [Abstract][Full Text] [Related]
17. Itraconazole therapy for cryptococcal meningitis and cryptococcosis.
Denning DW; Tucker RM; Hanson LH; Hamilton JR; Stevens DA
Arch Intern Med; 1989 Oct; 149(10):2301-8. PubMed ID: 2552949
[TBL] [Abstract][Full Text] [Related]
18. [The therapeutic effects of itraconazole, a new triazole antifungal agent, for experimental fungal infections].
Uchida K; Yamaguchi H; Shibuya K
Jpn J Antibiot; 1991 May; 44(5):588-99. PubMed ID: 1652657
[TBL] [Abstract][Full Text] [Related]
19. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.
Hossain MA; Maesaki S; Mitsutake K; Kakeya H; Sasaki E; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1999 Dec; 44(6):827-9. PubMed ID: 10590286
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.
Hata K; Kimura J; Miki H; Toyosawa T; Moriyama M; Katsu K
Antimicrob Agents Chemother; 1996 Oct; 40(10):2243-7. PubMed ID: 8891122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
